Successful Treatment of Terbinafine-Induced Subacute Cutaneous Lupus Erythematosus With Upadacitinib

Main Article Content

Chloe H Franzia
Glazer Dermatology

Grace Sclamberg
Alex M Glazer

Keywords

DI-SCLE, Upadacitinib

Abstract

Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is now the most common form of drug-induced lupus erythematosus (DI-LE). Terbinafine is a well-established DI-SCLE trigger and most cases resolve with traditional therapies, such as topical and oral steroids. However, some cases may be more persistent and refractory to these treatments, or patients may be unable to tolerate systemic steroid use due to underlying conditions. These challenges highlight the limitations of conventional therapies, underscoring the need for alternative treatments in difficult to treat or protracted cases. This report presents a case of terbinafine-induced SCLE that was unresponsive to systemic steroids and quickly resolved with a short course of upadacitinib, an oral selective JAK-1 inhibitor.

References

1. Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus. 2009;18(11):935-940. doi:10.1177/0961203309106176

2. HOFFMAN BJ. SENSITIVITY TO SULFADIAZINE RESEMBLING ACUTE DISSEMINATED LUPUS ERYTHEMATOSUS. Arch Dermatol Syphilol. 1945;51(3):190-192. doi:10.1001/archderm.1945.01510210032007

3. Antonov D, Kazandjieva J, Etugov D, Gospodinov D, Tsankov N. Drug-induced lupus erythematosus. Clin Dermatol. 2004;22(2):157-166. doi:10.1016/j.clindermatol.2003.12.023

4. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301(1):99-105. doi:10.1007/s00403-008-0895-5

5. Uetrecht J. Current trends in drug-induced autoimmunity. Autoimmun Rev. 2005;4(5):309-314. doi:10.1016/j.autrev.2005.01.002

6. Callen JP, Hughes AP, Kulp-Shorten C. Subacute Cutaneous Lupus Erythematosus Induced or Exacerbated by Terbinafine: A Report of 5 Cases. Arch Dermatol. 2001;137(9):1196-1198. doi:10.1001/archderm.137.9.1196

7. Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol. 2001;137(9):1196-1198. doi:10.1001/archderm.137.9.1196

8. Bonsmann G, Schiller M, Luger TA, Ständer S. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2001;44(6):925-931. doi:10.1067/mjd.2001.114565

9. Keyes E, Grinnell M, Vazquez T, Diaz D, Thomas P, Werth VP. Drug-induced subacute cutaneous lupus erythematosus in previously diagnosed systemic lupus erythematosus patients: A case series. JAAD Case Rep. 2021;12:18-21. doi:10.1016/j.jdcr.2021.03.048

10. Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to Antimalarial Agents in Cutaneous Lupus Erythematosus: A Prospective Analysis. Arch Dermatol. 2011;147(11):1261-1267. doi:10.1001/archdermatol.2011.191

11. Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2023;17(1):e13688. doi:10.1111/cts.13688

12. Hu W, Zhang S, Lian C. Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report. Clin Cosmet Investig Dermatol. 2023;16:2793-2800. doi:10.2147/CCID.S419344

Article Sidebar

PDF
Published
Mar 17, 2025
DOI https://doi.org/10.25251/skin.9.2.10

Article Details

How to Cite
[1]
Franzia, C.H., Sclamberg, G. and Glazer, A.M. 2025. Successful Treatment of Terbinafine-Induced Subacute Cutaneous Lupus Erythematosus With Upadacitinib. SKIN The Journal of Cutaneous Medicine. 9, 2 (Mar. 2025), 2232–2235. DOI:https://doi.org/10.25251/skin.9.2.10.
Issue
Vol. 9 No. 2 (2025): March 2025 Issue
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.